Overall, the safety profile of the combination therapy was consistent with previous clinical trials with nintedanib and the known safety profile of docetaxel, with the most common drug-related AEs being myelotoxicity (neutropenia and leukopenia), liver enzyme elevations (increased AST and ALT), gastrointestinal AEs (diarrhea and nausea), and alopecia. This evidence concerns the gene GPT and Decreased total leukocyte count.